News

Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a) is designed to reduce Lp(a) by

The new facility will be spread over 100,000ft² plot and the company will first begin work on an oral solid unit and thereafter set up manufacturing units for

Octagam 10% [immune globulin intravenous (human) 10% (100mg/ml) liquid preparation] helps in rapidly raising platelet counts to control or prevent bleeding in chronic ITP patients. The FDA approval

Currently, nintedanib is under FDA and European Medicines Agency (EMA review) to be indicated for the treatment of IPF. Boehringer Ingelheim chief medical officer Klaus Dugi said the

The company is focused on developing first-in-class platform of therapeutics to address pain at its molecular roots. With ADYX-003, the company will build on the results of the

By using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, the companies will seek to use the power of the body’s own immune system to attack

Imugene’ cancer immunotherapy vaccine candidate HER-Vaxx is scheduled to enter into a Phase I/II clinical trial in 2015. Under the deal, Mymetics will use its strong experience and

The Phase 1/2 study, taking place at Tampere Hospital in Finland, a world-leading site for celiac disease research, is a two-part (single and repeated administration), double-blind, placebo-controlled, dose

Basilea’s co-development partner Astellas Pharma Inc. also recently submitted a New Drug Application (NDA) for isavuconazole to the U.S. Food and Drug Administration (FDA). Ronald Scott, Basilea’s Chief